177 related articles for article (PubMed ID: 16467119)
21. The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy.
Zhang Y; Sieuwerts AM; McGreevy M; Casey G; Cufer T; Paradiso A; Harbeck N; Span PN; Hicks DG; Crowe J; Tubbs RR; Budd GT; Lyons J; Sweep FC; Schmitt M; Schittulli F; Golouh R; Talantov D; Wang Y; Foekens JA
Breast Cancer Res Treat; 2009 Jul; 116(2):303-9. PubMed ID: 18821012
[TBL] [Abstract][Full Text] [Related]
22. RT-PCR-based gene expression profiling for cancer biomarker discovery from fixed, paraffin-embedded tissues.
Scott A; Ambannavar R; Jeong J; Liu ML; Cronin MT
Methods Mol Biol; 2011; 724():239-57. PubMed ID: 21370017
[TBL] [Abstract][Full Text] [Related]
23. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
24. [Predictive and prognostic markers of breast cancer. Molecular biological analysis of fixed tumor tissue].
Petry C; Gehrmann M; von Törne C; Weber K; Stropp U; Hennig G
Pathologe; 2008 Nov; 29 Suppl 2():181-3. PubMed ID: 18843491
[TBL] [Abstract][Full Text] [Related]
25. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.
Buzdar A; Chlebowski R; Cuzick J; Duffy S; Forbes J; Jonat W; Ravdin P
Curr Med Res Opin; 2006 Aug; 22(8):1575-85. PubMed ID: 16870082
[TBL] [Abstract][Full Text] [Related]
26. [The value of gene expression profiles using micoarrays for the individualisation of adjuvant therapy after surgery for breast cancer].
Klijn JG; de Vries EG
Ned Tijdschr Geneeskd; 2005 Mar; 149(12):618-22. PubMed ID: 15813427
[TBL] [Abstract][Full Text] [Related]
27. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
Monnier AM
Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927
[TBL] [Abstract][Full Text] [Related]
28. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
[TBL] [Abstract][Full Text] [Related]
29. Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet?
Correa Geyer F; Reis-Filho JS
Int J Surg Pathol; 2009 Aug; 17(4):285-302. PubMed ID: 19103611
[TBL] [Abstract][Full Text] [Related]
30. Commercialized multigene predictors of clinical outcome for breast cancer.
Ross JS; Hatzis C; Symmans WF; Pusztai L; Hortobágyi GN
Oncologist; 2008 May; 13(5):477-93. PubMed ID: 18515733
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant endocrine therapy for postmenopausal women with early breast cancer.
Ingle JN
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1031s-1036s. PubMed ID: 16467121
[TBL] [Abstract][Full Text] [Related]
32. Integrated gene expression profile predicts prognosis of breast cancer patients.
Li LF; Xu XJ; Zhao Y; Liu ZB; Shen ZZ; Jin WR; Shao ZM
Breast Cancer Res Treat; 2009 Jan; 113(2):231-7. PubMed ID: 18278552
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
[TBL] [Abstract][Full Text] [Related]
34. Genomic testing for sensitivity of breast cancer to hormonal therapy.
Symmans WF
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1954-5. PubMed ID: 16609001
[No Abstract] [Full Text] [Related]
35. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD
J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417
[TBL] [Abstract][Full Text] [Related]
36. Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen.
Paik S
Oncologist; 2007 Jun; 12(6):631-5. PubMed ID: 17602054
[TBL] [Abstract][Full Text] [Related]
37. Molecular profiling of breast cancer.
Paik S
Curr Opin Obstet Gynecol; 2006 Feb; 18(1):59-63. PubMed ID: 16493262
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.
Dowsett M; Smith IE; Ebbs SR; Dixon JM; Skene A; A'Hern R; Salter J; Detre S; Hills M; Walsh G;
J Natl Cancer Inst; 2007 Jan; 99(2):167-70. PubMed ID: 17228000
[TBL] [Abstract][Full Text] [Related]
39. Current status of prognostic profiling in breast cancer.
Pusztai L
Oncologist; 2008 Apr; 13(4):350-60. PubMed ID: 18448548
[TBL] [Abstract][Full Text] [Related]
40. Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancer.
Pusztai L; Broglio K; Andre F; Symmans WF; Hess KR; Hortobagyi GN
J Clin Oncol; 2008 Oct; 26(28):4679-83. PubMed ID: 18662965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
